Mind Medicine (MindMed) (MNMD) Stock Forecast, Price Target & Predictions
MNMD Stock Forecast
Mind Medicine (MindMed) stock forecast is as follows: an average price target of $21.00 (represents a 225.58% upside from MNMD’s last price of $6.45) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MNMD Price Target
MNMD Analyst Ratings
Mind Medicine (MindMed) Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 05, 2024 | Brian Abrahams | RBC Capital | $22.00 | $8.25 | 166.67% | 241.09% |
May 13, 2024 | Francois Brisebois | Oppenheimer | $20.00 | $8.61 | 132.42% | 210.08% |
Nov 16, 2022 | - | RBC Capital | $5.00 | $2.86 | 74.83% | -22.48% |
Mind Medicine (MindMed) Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $21.00 |
Last Closing Price | $6.45 | $6.45 | $6.45 |
Upside/Downside | -100.00% | -100.00% | 225.58% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jun 05, 2024 | RBC Capital | Outperform | Outperform | Hold |
May 13, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Nov 16, 2022 | RBC Capital | - | Outperform | Initialise |
Aug 26, 2022 | Oppenheimer | - | Outperform | Initialise |
Mind Medicine (MindMed) Financial Forecast
Mind Medicine (MindMed) Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed) EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed) Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-23.55M | $-25.71M | $-24.99M | $-24.63M | $-21.72M | $-19.92M | $-23.52M |
High Forecast | $-23.55M | $-25.71M | $-24.99M | $-24.63M | $-21.72M | $-18.55M | $-23.52M |
Low Forecast | $-23.55M | $-25.71M | $-24.99M | $-24.63M | $-21.72M | $-21.29M | $-23.52M |
Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed) SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed) EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.33 | $-0.36 | $-0.35 | $-0.34 | $-0.30 | $-0.28 | $-0.33 |
High Forecast | $-0.33 | $-0.36 | $-0.35 | $-0.34 | $-0.30 | $-0.26 | $-0.33 |
Low Forecast | $-0.33 | $-0.36 | $-0.35 | $-0.34 | $-0.30 | $-0.30 | $-0.33 |
Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed) Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
KOD | Kodiak Sciences | $2.71 | $32.80 | 1110.33% | Buy |
CKPT | Checkpoint Therapeutics | $2.30 | $20.00 | 769.57% | Buy |
RVPH | Reviva Pharmaceuticals | $1.20 | $10.00 | 733.33% | Buy |
MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
ATAI | Atai Life Sciences | $1.30 | $6.00 | 361.54% | Buy |
OPT | Opthea | $3.15 | $14.00 | 344.44% | Buy |
GHRS | GH Research | $8.30 | $31.00 | 273.49% | Buy |
MNMD | Mind Medicine (MindMed) | $6.45 | $21.00 | 225.58% | Buy |
EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
ITOS | iTeos Therapeutics | $16.70 | $38.50 | 130.54% | Buy |
ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
MNMD Forecast FAQ
Is Mind Medicine (MindMed) a good buy?
Yes, according to 2 Wall Street analysts, Mind Medicine (MindMed) (MNMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of MNMD's total ratings.
What is MNMD's price target?
Mind Medicine (MindMed) (MNMD) average price target is $21 with a range of $20 to $22, implying a 225.58% from its last price of $6.45. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Mind Medicine (MindMed) stock go up soon?
According to Wall Street analysts' prediction for MNMD stock, the company can go up by 225.58% (from the last price of $6.45 to the average price target of $21), up by 241.09% based on the highest stock price target, and up by 210.08% based on the lowest stock price target.
Can Mind Medicine (MindMed) stock reach $10?
MNMD's average twelve months analyst stock price target of $21 supports the claim that Mind Medicine (MindMed) can reach $10 in the near future.
What are Mind Medicine (MindMed)'s analysts' financial forecasts?
Mind Medicine (MindMed)'s analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-65.153M (high $-63.779M, low $-66.526M), average SG&A $0 (high $0, low $0), and average EPS is $-0.906 (high $-0.887, low $-0.925). MNMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-98.879M (high $-98.879M, low $-98.879M), average SG&A $0 (high $0, low $0), and average EPS is $-1.375 (high $-1.375, low $-1.375).